Molecular Partners Presents Positive Initial Data from First Four Dosing Cohorts of Ongoing Phase 1/2a Trial of MP0533 for Patients with Relapsed/Refractory AML and AML/MDS at ASH Annual Meeting
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Dec. 10, 2023 (GLOBE NEWSWIRE) — Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ:MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today presented positive initial clinical data from its ongoing Phase 1/2a trial of MP0533, a novel tetra-specific T cell engager, in a poster at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition. These data, which highlight encouraging initial safety and antitumor activity, expand upon those previously disclosed in the conference abstract.
Related news for (MOLN)
- Molecular Partners and Orano Med Share Positive DLL3 Preclinical Data
- Molecular Partners Provides Updates at 42nd Annual J.P. Morgan Healthcare Conference
- Molecular Partners to Present at 42nd Annual J.P. Morgan Healthcare Conference and Swiss Investor Conferences
- Molecular Partners Publishes Invitation to Annual General Meeting 2023